SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : Kirk's Market Thoughts -- Ignore unavailable to you. Want to Upgrade?


To: w0z who wrote (26506)11/15/2025 6:22:18 PM
From: Kirk ©  Read Replies (1) | Respond to of 27055
 
Thanks for the update. I tried to verify the cash position and both Yahoo! and Fidelity were still on the June quarter so only showing $75M BUT I checked the 11/13/25 PR and found this good news:
Successfully completed three rounds of equity financing with three institutional investors at prices ranging from $5.00 to $7.25 per share for gross proceeds of $250,000,000.
I've done pretty well with speculations looking to buy at a discount to what the big buyers paid.

and

fidelity.com/news/article/technology/202510261831PRIMZONEFULLFEED9562284
“POET’s Optical Interposer platform is a singularly elegant solution to connectivity challenges at each level of AI infrastructure, from chip-to-chip data communications to data transfer within the datacenter to the mobile networks that deliver that data to users”, said Dr. Suresh Venkatesan, Executive Chairman & Chief Executive Officer of POET. “In each of these areas, we transform information bottlenecks into data highways by marrying what is possible in silicon to what is powerful in light. This additional investment by two leading global investment funds adds immeasurably to POET’s ability to deliver advanced photonic solutions. With over US$300 million in cash, we can accelerate our pursuit of targeted acquisitions, enhance our capabilities and talent, vertically integrate our products to improve cost and performance, and expand operations to pursue revenue opportunities across the board, bringing long-term value to shareholders.”


It looks pretty similar (financially) to my AGEN with outsiders buying shares at $7.50 in an offering that drove the stock price up before settling now at $4.34 even after announcing making $2 a share this quarter from I believe selling some of its MiNK subsidy to go under 50% and raise $100M or so. AGEN has demonstrated cures for untreatable cancer in two patients and has "orders" for phase three testing funded by others... much like POET's small $5M order.

So, if I read you correctly, you still have a large position in actual shares, slightly reduced to fund/diversify into HGRAF then rather than trade around this core position, you use leaps for more leverage?

I might consider some for my ROTH that has done really well converting cash from my IRA when it is down then buying beaten down stocks like COHR to ride back up for nice, tax-free gains. Trouble is often this "extra risk taking" from stocks mentioned by the K2 climber often land me in a crevasse at a time I should be getting more conservative (ie market tops.)

Thanks again for the update.